Mesintel has developed a proprietary target discovery platform that incorporates our extensive knowledge of mesenchymal progenitor (MP) biology, coupled with disease-specific datasets mined by state-of-the-art AI/ML capabilities. The platform is designed to accelerate the development of therapeutics centered around the key role MPs play in driving disease, including rare oncology and the solid tumor microenvironment. These efforts will enable Mesintel to leverage its platform into complementary therapeutic areas, such as rare disease, fibrosis, tissue regeneration and aging. We are seeking opportunities to propel collaborative discovery and development partnerships, and seed funding to advance internal programs and platform capabilities.